IN2014MN02512A - - Google Patents

Info

Publication number
IN2014MN02512A
IN2014MN02512A IN2512MUN2014A IN2014MN02512A IN 2014MN02512 A IN2014MN02512 A IN 2014MN02512A IN 2512MUN2014 A IN2512MUN2014 A IN 2512MUN2014A IN 2014MN02512 A IN2014MN02512 A IN 2014MN02512A
Authority
IN
India
Prior art keywords
diseases
substituted
active ingredient
arteriosclerosis
agent
Prior art date
Application number
Other languages
English (en)
Inventor
Hideki Kobayashi
Nobuyuki Ohkawa
Daisuke Takano
Hideki Kubota
Toshio Onoda
Toshio Kaneko
Masami Arai
Naoki Terasaka
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of IN2014MN02512A publication Critical patent/IN2014MN02512A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN2512MUN2014 2012-06-14 2013-06-13 IN2014MN02512A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012134431 2012-06-14
PCT/JP2013/066306 WO2013187462A1 (fr) 2012-06-14 2013-06-13 Dérivé de pipéridinylpyrazolopyridine

Publications (1)

Publication Number Publication Date
IN2014MN02512A true IN2014MN02512A (fr) 2015-07-17

Family

ID=49758280

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2512MUN2014 IN2014MN02512A (fr) 2012-06-14 2013-06-13

Country Status (13)

Country Link
US (1) US9150575B2 (fr)
EP (1) EP2862861B1 (fr)
JP (1) JPWO2013187462A1 (fr)
KR (1) KR20150021036A (fr)
CN (1) CN104781257A (fr)
BR (1) BR112014030954A2 (fr)
CA (1) CA2876382A1 (fr)
ES (1) ES2563861T3 (fr)
HK (1) HK1207375A1 (fr)
IN (1) IN2014MN02512A (fr)
RU (1) RU2015100942A (fr)
TW (1) TW201402572A (fr)
WO (1) WO2013187462A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968297B1 (fr) 2013-03-15 2018-09-26 Verseon Corporation Composés aromatiques multisubstitués en tant qu'inhibiteurs de sérine protéase
WO2015050148A1 (fr) * 2013-10-04 2015-04-09 第一三共株式会社 Dérivé de 3-arylpyrazolopyridine
WO2015076353A1 (fr) * 2013-11-25 2015-05-28 第一三共株式会社 Dérivé 3-alkylpyrazolopyridine
WO2015087996A1 (fr) * 2013-12-13 2015-06-18 第一三共株式会社 Dérivé d'imidazopyridine
WO2015087995A1 (fr) * 2013-12-13 2015-06-18 第一三共株式会社 Dérivé cycloalkyle ou hétérocyclyle de pyrazolopyridine
KR20160096612A (ko) * 2013-12-13 2016-08-16 다이이찌 산쿄 가부시키가이샤 5-하이드록시-4-(트리플루오로메틸)피라졸로피리딘 유도체
CN103694220A (zh) * 2013-12-30 2014-04-02 张磊 新型吡唑-3-甲酸酯及合成方法
WO2015111545A1 (fr) * 2014-01-21 2015-07-30 第一三共株式会社 Dérivé condensé de pyrazole
WO2016044662A1 (fr) 2014-09-17 2016-03-24 Verseon Corporation Composés de pyridone substituée par pyrazolyl en tant qu'inhibiteurs de sérine protéase
WO2016138532A1 (fr) * 2015-02-27 2016-09-01 Verseon Corporation Composés pyrazole substitués à utiliser en tant qu'inhibiteurs de sérine protéase
TWI713534B (zh) * 2015-06-11 2020-12-21 日商第一三共股份有限公司 5-羥基-4-(三氟甲基)吡唑并吡啶衍生物之結晶及其用途
CN106916143B (zh) * 2017-03-14 2019-09-27 哈尔滨医科大学 一种预防和治疗冠心病的药物及其应用
US20210024520A1 (en) 2018-03-30 2021-01-28 Daiichi Sankyo Company, Limited Therapeutic agent for lcat deficiency
CN116075511A (zh) * 2020-04-09 2023-05-05 达萨玛治疗公司 作为sarm1抑制剂的稠合吡唑衍生物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019200A2 (fr) 2003-08-14 2005-03-03 Icos Corporation Derives d'arylpiperidine utilises en tant qu'antagonistes d'integrine vla-1 et utilisations de ceux-ci
CA2564561A1 (fr) 2004-04-28 2005-11-10 Merck & Co., Inc. Modulateurs de l'activite de recepteurs de chimiokines en tetrahydropyranylcyclopentylamide disubstitue en position 3,3
SE0403171D0 (sv) 2004-12-23 2004-12-23 Astrazeneca Ab New compounds
US20100234395A1 (en) 2006-03-27 2010-09-16 Toray Industries, Inc. Ureide derivative and pharmaceutical application thereof
WO2008002591A2 (fr) 2006-06-26 2008-01-03 Amgen Inc Procédés de traitement de l'athérosclérose
PT2125794E (pt) 2006-12-21 2011-01-10 Lilly Co Eli Compostos imidazolidinonilo aminopirimidina para o tratamento do cancro
CA2913840C (fr) 2007-04-11 2019-03-05 Canbas Co., Ltd. Composes presentant une activite anti-cancereuse
CA2699787A1 (fr) 2007-09-24 2009-04-02 Comentis, Inc. Derives de (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide et composes associes utilises en tant qu'inhibiteurs de la beta-secretase pour le traitement
EP2080758A3 (fr) 2007-11-29 2009-08-26 Bayer CropScience AG Delta-1-pyrrolines substituées par halogène
EP2236494B1 (fr) 2007-12-26 2016-08-31 Msd K.K. Dérivé de noyau à six chaînons à substitution sulphonyle
MX2010010504A (es) 2008-03-26 2010-12-15 Daiichi Sankyo Co Ltd Derivado de hidroxi-quinoxalin-carboxamida.
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
US8394834B2 (en) 2009-08-25 2013-03-12 Hoffman-La Roche Inc. Pyrrolidines as NK3 receptor antagonists
WO2011041152A1 (fr) 2009-09-30 2011-04-07 Schering Corporation Nouveaux composés inhibiteurs d'erk
FR2951172B1 (fr) 2009-10-13 2014-09-26 Pf Medicament Derives pyrazolopyridines en tant qu'agent anticancereux
CA2804716A1 (fr) 2010-07-12 2012-01-19 Pfizer Limited Composes chimiques
WO2012028243A1 (fr) * 2010-09-02 2012-03-08 Merck Patent Gmbh Dérivés de pyrazolopyridinone en tant qu'antagonistes de récepteur de lpa

Also Published As

Publication number Publication date
EP2862861A1 (fr) 2015-04-22
JPWO2013187462A1 (ja) 2016-02-08
WO2013187462A1 (fr) 2013-12-19
BR112014030954A2 (pt) 2017-06-27
EP2862861A4 (fr) 2015-04-22
TW201402572A (zh) 2014-01-16
KR20150021036A (ko) 2015-02-27
US9150575B2 (en) 2015-10-06
ES2563861T3 (es) 2016-03-16
EP2862861B1 (fr) 2016-01-06
HK1207375A1 (en) 2016-01-29
RU2015100942A (ru) 2016-08-10
CN104781257A (zh) 2015-07-15
US20150152102A1 (en) 2015-06-04
CA2876382A1 (fr) 2013-12-19

Similar Documents

Publication Publication Date Title
IN2014MN02512A (fr)
PH12016501129B1 (en) 5-hydroxy-4-(trifluoromethyl)pyrazolopyridine derivative
CO7180199A2 (es) Imidazotriazincarbonitrilos útiles como inhibidores de cinasa
WO2013019561A8 (fr) Modulateurs de transport nucléaire et leurs utilisations
BR112012019672A2 (pt) pirrolidina-2-carboxamidas substituídas.
MY170326A (en) Imidazo [1,2-b] pyridazine derivativea as kinase inhibitors
MX2013010552A (es) Compuestos de guanidina.
NZ627250A (en) Novel nicotinamide derivative or salt thereof
WO2010122980A8 (fr) Nouvel agoniste du récepteur ss de l'hormone thyroïdienne
JO3387B1 (ar) مشتقات بيتولين
WO2011012816A3 (fr) Formulation pharmaceutique
CO6511269A2 (es) Derivados de imidazol sustituido con cicloaquilo
PH12018500261B1 (en) Azole benzene derivative
WO2013020024A3 (fr) Composés de maléimide et méthodes de traitement
IN2014CN04449A (fr)
WO2014036502A3 (fr) Composés de tétracyclines
TN2012000092A1 (en) Therapeutic agent for mood disorders
NZ603465A (en) Antimalarial drug which contains 5-aminolevulinic acid or derivative thereof as active ingredient
WO2014172188A3 (fr) Composés dérivés de 4-pyridone et leurs utilisations en tant qu'inhibiteurs de la vih intégrase
IN2014DN05972A (fr)
WO2010132670A3 (fr) Composés pentacyclines
PH12015501056A1 (en) 2-pyridone compound
WO2013062332A3 (fr) Composition anti-vieillissement vasculaire comprenant du syringarésinol
TH137484A (th) อนุพันธ์ไซโคลแอลคิล-ซับสทิทิวเทดอิมิดาโซล
MX2019012810A (es) Compuesto heterociclico.